IAS-USA Updates Adult ART Treatment and Prevention Guidelines
Key Insights
A 15-member expert panel reviewed 539 peer-reviewed articles published through August 22, 2020 to update the 2018 IAS-USA antiretroviral therapy recommendations.
The updated guidance further endorses mostly integrase strand inhibitor-based regimens and tacitly recommends injectable long-acting antiretrovirals for treatment and prevention in certain populations.
ART is recommended for all persons with detectable viremia and usually should be started as soon as possible, with most patients able to begin any of various three-drug regimens.
The International Antiviral Society-USA (search) has issued updated recommendations for antiretroviral therapy (ART) and prevention in adults, reflecting further endorsement of mostly integrase strand inhibitor-based regimens and a tacit recommendation of injectable long-acting antiretroviral drugs for treatment and prevention in certain populations.
A panel of 15 HIV (search) experts reviewed 539 recent peer-reviewed articles through August 22, 2020 to rate and update the 2018 ART recommendations. The guidelines state that ART is recommended for all persons with detectable viremia and that treatment usually should be started as soon as possible. Most patients can be treated initially with any of various three-drug ART regimens or, in select populations, a two-drug regimen containing an integrase strand transfer inhibitor (search).
Specific recommendations address certain patient groups, including pregnant women, persons with significant comorbidities, and those with common opportunistic infections.